One aerospace stock got hit by a SpaceX announcement. Two analysts say buy the dip
Howmet Aerospace (HWM) fell 8% after SpaceX announced plans to produce its own industrial gas turbine castings. Citigroup and Bernstein reiterated buy ratings, citing Howmet's market dominance and long-term agreements, with price targets of $329 and $328 respectively, implying ~34% upside. Howmet is down 13% in a month but up 19.5% YTD and 41% over the past year.
How this was made
The 30-second read
Why it matters
The SpaceX announcement triggered an immediate price drop, but analysts view it as a short‑term overreaction, reaffirming buy ratings and setting higher price targets.
Market read
The news creates a short‑term trading opportunity in HWM, with analysts expecting a rebound despite the SpaceX competitive threat.
What to watch
Potential cost overruns for SpaceX's new production line and the long‑term nature of Howmet's contracts could limit upside.
Background
Howmet Aerospace (HWM) is a leading supplier of cast components for industrial gas turbines, serving data center power markets.
Ticker impact
Howmet Aerospace fell ~8% after SpaceX announced it will make its own castings for industrial gas turbines, prompting analyst buy ratings and new price targets.
Potential rebound toward price targets over the next weeks.
Analyst coverage and price‑target upgrades are fresh and directly tied to the same‑day catalyst.
Market effects
Industrial gas turbine casting market may see increased competition, but Howmet retains >50% share.
U.S. aerospace and defense sector could see modest re‑rating.
SpaceX's move signals broader trend of vertical integration in aerospace supply chains.
Counterpoint
If SpaceX successfully scales its own castings, Howmet could lose market share, making the dip a warning rather than a buying chance.
Key entities
- CompanySpaceX
Aerospace manufacturer planning to produce its own turbine castings.
- Financial InstitutionCitigroup
Analyst firm reiterating buy rating and setting $329 target.
- Financial InstitutionBernstein
Analyst firm reiterating outperform rating and $328 target.
